Coherus Claims COVID Delays As It Axes Avastin Biosimilar Program

Ending Innovent’s Avastin Partnership ‘Unfortunate Business Decision’

Coherus BioSciences, juggling both biosimilar and novel biologic assets, has called time on its partnership with China’s Innovent Biologics for biosimilar Avastin – a year after shelving development of biosimilar Eylea.

severing ties and boycott concept
Coherus has severed another of its biosimilar programs • Source: Shutterstock

A shrinking market opportunity caused by “significant” COVID-related delays in the development program has led Coherus BioSciences, Inc. to terminate its CHS-305 Avastin (bevacizumab) biosimilar and return North American rights to partner Innovent Biologics.

“The clinical trials were difficult in a number of things, so we lost a substantial amount of time with the...

Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

More from Biosimilars

More from Products

  • For Generics, A Victory Lap – And A Warning – On Drug Shortages

    Avoiding disaster at the beginning of the pandemic and offering a pro-active supply chain blueprint should position the generics industry well for an onshoring debate in Congress, but a look back at March 2020 is a reminder that even small policy shifts can have a big impact.

  • GB-Free-Company-The Secret to Walking More: It’s Not Counting Steps

    We’ve all been told that walking 10,000 steps a day is the magic number for better health. But what if the real secret to walking more isn’t about counting steps at all? In this article, we explore how focusing on motivation, environment, and mindset can help you build a walking habit that lasts.

  • Biocon And Teva Sign Up To Biosimilars Forum

    Teva and Biocon Biologics have become the latest firms to sign up to the Biosimilars Forum industry association in the US.